IDBS included in recent research report from Gartner

NewsGuard 100/100 Score

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that it has been included in a recent research report from Gartner, "Who's Who in Interactive Visualization for BI," by James Richardson, published November 13, 2009.

According to Gartner, "interactive visualization helps business intelligence (BI) become more usable and insightful." Moreover, "whether it is incorporated into a dashboard or exists as a stand-alone analysis tool, better interactive visualization is a valuable addition to the BI platform, as it applies users' innate visual ability to aid understanding of patterns, for example, in a much more effective fashion than tabulated figures."

IDBS' VisualSense was named in the report for its advanced visual analytics capabilities. VisualSense is a component of the IDBS InforSense Suite for data integration, analysis and visualization, which helps organizations to make the most effective use of critical scientific data. With VisualSense, scientists and researchers can use highly interactive web-based reports and dashboards that enable them to quickly and easily spot trends in data, see deviations from those trends, identify outliers and detect data quality issues that might otherwise go unnoticed.

VisualSense provides a comprehensive set of charts, including heat maps, scatter plots and trellis views, as well as interactive capabilities that allow groups of data points to be selected and further analyzed, or that enable outliers to be deleted and curves recalculated. This level of interaction helps researchers to understand research and development data more quickly.

"We are delighted to be included in this Gartner report, which we believe reflects our valuable and unique scientific data analysis and visualization capabilities," said Neil Kipling, founder and CEO of IDBS. "The InforSense Suite plays a critical role in translational and biomarker research at leading drug discovery and medical research organizations around the world. With version 5.1 of the InforSense Suite launching in early 2010, users will have even more control over their visualizations. We consider this report further validation of the effectiveness and usability of our innovative technologies. Not only does this reflect that we have the premier solution in the scientific space, but also that we can provide the features and benefits demonstrated by today's mainstream BI vendors."

SOURCE: IDBS

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer